HER2 status as a potential predictive biomarker for ovarian
clear cell carcinoma

J 2023

HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma

BARTU KENDALL, Michaela, Kristyna NEMEJCOVA, Romana MICHALKOVA, Ivana STRUZINSKA, Nikola HAJKOVA et. al.

Basic information

Original name

HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma

Authors

BARTU KENDALL, Michaela (203 Czech Republic), Kristyna NEMEJCOVA (203 Czech Republic), Romana MICHALKOVA (203 Czech Republic), Ivana STRUZINSKA (203 Czech Republic), Nikola HAJKOVA (203 Czech Republic), Jan HOJNY (203 Czech Republic), Eva KRKAVCOVA (203 Czech Republic), Jan LACO (203 Czech Republic), Radoslav MATEJ (203 Czech Republic), Jana DROZENOVA (203 Czech Republic), Gabor MEHES (203 Czech Republic), Pavel FABIAN (203 Czech Republic), Jitka HAUSNEROVÁ (203 Czech Republic, belonging to the institution), Marian SVAJDLER (203 Czech Republic), Petr SKAPA (203 Czech Republic), David CIBULA (203 Czech Republic), Tomas ZIMA (203 Czech Republic) and Pavel DUNDR (203 Czech Republic)

Edition

Virchows Archiv, New York, Springer, 2023, 0945-6317

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30109 Pathology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.500 in 2022

RIV identification code

RIV/00216224:14110/23:00132982

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1007/s00428-023-03640-4

UT WoS

001060259500001

Keywords in English

HER2; Ovarian clear cell carcinoma; Immunohistochemistry; Gynecopathology; Ovarian cancer

Abstract

V originále

Ovarian clear cell carcinoma (OCCC) is a subtype of ovarian carcinoma characterized by unique biological features and highly malignant characteristics including low chemosensitivity. Therefore, new therapeutic targets are needed. These could include the downstream pathways of receptor tyrosine kinases, especially the human epidermal growth factor receptor 2 (HER2). Our main objective was to characterize the HER2 status using immunohistochemistry (IHC) and FISH on 118 OCCCs, also considering the novel paradigm of HER2-zero and HER2-low status. Other aims included determination of the association between HER2 status and survival, HER2 gene DNA and RNA NGS analysis, HER2 gene expression analysis, and correlation between IHC and gene expression in HER2-zero and HER2-low cases. Cases with HER2 overexpression/amplification accounted for 5.1% (6/118), with additional 3% harbouring HER2 gene mutation. The remaining 112 (94.9%) cases were HER2-negative. Of these, 75% were classified as HER2-zero and 25% as HER2-low. This percentage of HER2 aberrations is significant concerning their possible therapeutic influence. Cases from the HER2-zero group showed significantly better survival. Although this relationship lost statistical significance in multivariate analysis, the results have potential therapeutic significance. HER2 gene expression analysis showed a significant correlation with HER2 IHC status in the entire cohort (HER2-positive vs. HER2-negative), while in the cohort of only HER2-negative cases, the results did not reach statistical significance, suggesting that gene expression analysis would not be suitable to confirm the subdivision into HER2-low and HER2-zero. Our results also emphasize the need for standardized HER2 testing in OCCC to determine the best predictor of clinical response.

Links

90233, large research infrastructures

Name: BBMRI.cz IV

Citovat

BARTU KENDALL, Michaela, Kristyna NEMEJCOVA, Romana MICHALKOVA, Ivana STRUZINSKA, Nikola HAJKOVA, Jan HOJNY, Eva KRKAVCOVA, Jan LACO, Radoslav MATEJ, Jana DROZENOVA, Gabor MEHES, Pavel FABIAN, Jitka HAUSNEROVÁ, Marian SVAJDLER, Petr SKAPA, David CIBULA, Tomas ZIMA and Pavel DUNDR. HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma. Virchows Archiv. New York: Springer, 2023, vol. 483, No 4, p. 497-507. ISSN 0945-6317. Available from: https://dx.doi.org/10.1007/s00428-023-03640-4.

@article{2360016,
   author = {Bartu Kendall, Michaela and Nemejcova, Kristyna and Michalkova, Romana and Struzinska, Ivana and Hajkova, Nikola and Hojny, Jan and Krkavcova, Eva and Laco, Jan and Matej, Radoslav and Drozenova, Jana and Mehes, Gabor and Fabian, Pavel and Hausnerová, Jitka and Svajdler, Marian and Skapa, Petr and Cibula, David and Zima, Tomas and Dundr, Pavel},
   article_location = {New York},
   article_number = {4},
   doi = {http://dx.doi.org/10.1007/s00428-023-03640-4},
   keywords = {HER2; Ovarian clear cell carcinoma; Immunohistochemistry; Gynecopathology; Ovarian cancer},
   language = {eng},
   issn = {0945-6317},
   journal = {Virchows Archiv},
   title = {HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma},
   url = {https://link.springer.com/article/10.1007/s00428-023-03640-4},
   volume = {483},
   year = {2023}
}

TY  - JOUR
ID  - 2360016
AU  - Bartu Kendall, Michaela - Nemejcova, Kristyna - Michalkova, Romana - Struzinska, Ivana - Hajkova, Nikola - Hojny, Jan - Krkavcova, Eva - Laco, Jan - Matej, Radoslav - Drozenova, Jana - Mehes, Gabor - Fabian, Pavel - Hausnerová, Jitka - Svajdler, Marian - Skapa, Petr - Cibula, David - Zima, Tomas - Dundr, Pavel
PY  - 2023
TI  - HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma
JF  - Virchows Archiv
VL  - 483
IS  - 4
SP  - 497-507
EP  - 497-507
PB  - Springer
SN  - 09456317
KW  - HER2
KW  - Ovarian clear cell carcinoma
KW  - Immunohistochemistry
KW  - Gynecopathology
KW  - Ovarian cancer
UR  - https://link.springer.com/article/10.1007/s00428-023-03640-4
N2  - Ovarian clear cell carcinoma (OCCC) is a subtype of ovarian carcinoma characterized by unique biological features and highly malignant characteristics including low chemosensitivity. Therefore, new therapeutic targets are needed. These could include the downstream pathways of receptor tyrosine kinases, especially the human epidermal growth factor receptor 2 (HER2). Our main objective was to characterize the HER2 status using immunohistochemistry (IHC) and FISH on 118 OCCCs, also considering the novel paradigm of HER2-zero and HER2-low status. Other aims included determination of the association between HER2 status and survival, HER2 gene DNA and RNA NGS analysis, HER2 gene expression analysis, and correlation between IHC and gene expression in HER2-zero and HER2-low cases. Cases with HER2 overexpression/amplification accounted for 5.1% (6/118), with additional 3% harbouring HER2 gene mutation. The remaining 112 (94.9%) cases were HER2-negative. Of these, 75% were classified as HER2-zero and 25% as HER2-low. This percentage of HER2 aberrations is significant concerning their possible therapeutic influence. Cases from the HER2-zero group showed significantly better survival. Although this relationship lost statistical significance in multivariate analysis, the results have potential therapeutic significance. HER2 gene expression analysis showed a significant correlation with HER2 IHC status in the entire cohort (HER2-positive vs. HER2-negative), while in the cohort of only HER2-negative cases, the results did not reach statistical significance, suggesting that gene expression analysis would not be suitable to confirm the subdivision into HER2-low and HER2-zero. Our results also emphasize the need for standardized HER2 testing in OCCC to determine the best predictor of clinical response.
ER  -

BARTU KENDALL, Michaela, Kristyna NEMEJCOVA, Romana MICHALKOVA, Ivana STRUZINSKA, Nikola HAJKOVA, Jan HOJNY, Eva KRKAVCOVA, Jan LACO, Radoslav MATEJ, Jana DROZENOVA, Gabor MEHES, Pavel FABIAN, Jitka HAUSNEROVÁ, Marian SVAJDLER, Petr SKAPA, David CIBULA, Tomas ZIMA and Pavel DUNDR. HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma. \textit{Virchows Archiv}. New York: Springer, 2023, vol.~483, No~4, p.~497-507. ISSN~0945-6317. Available from: https://dx.doi.org/10.1007/s00428-023-03640-4.

Detailed Information on Publication Record